Patients in situations like this would likely benefit from targeting tumor dormancy with further immunotherapy strategies such as cytokines (IL-15) that reinvigorate antitumor effector cells such as NK cells and CD8+ T cells50,51. This evidence concerns the gene CD8A and neoplasm.